Bayer announces U.S. FDA accepts new drug applications and grants priority review for investigational drug Finerenone for patients with chronic kidney disease and type 2 diabetes
Submission to FDA was based on positive data from Phase III FIDELIO-DKD study recently published in the New England Journal of Medicine WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA)